Transdermal iontophoretic delivery of selegiline hydrochloride, in vitro

Journal of Drug Targeting

Volumn 18, Issue 9, 2010, Pages 657-664

  Kolli, Chandra Sekhar ^a   Chadha, Gurkishan ^b   Xiao, Jin ^b   Parsons, Daniel L ^b   Babu, R Jayachandra ^b  

^a California Northstate College of Pharmacy   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Iontophoresis; Passive delivery; Selegiline; Transdermal

Indexed keywords

SELEGILINE; SODIUM CHLORIDE;

ARTICLE; CLINICAL EVALUATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TRANSPORT; ELECTRIC FIELD; HUMAN; HUMAN CELL; IN VITRO STUDY; IONTOPHORESIS; PH; PRIORITY JOURNAL; SKIN;

ADMINISTRATION, CUTANEOUS; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN-ION CONCENTRATION; IONTOPHORESIS; PERMEABILITY; SELEGILINE; SKIN ABSORPTION;

EID: 77957781765     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903494237     Document Type: Article

References (29)

1. Alvarez-Figueroa MJ, González-Aramundiz JV. (2008). Passive and iontophoretic transdermal penetration of chlorpromazine. Pharm Dev Technol, 13: 271-275.
2. Anderson MC, Hasan F, McCrodden JM, Tipton KF. (1993). Monoamine oxidase inhibitors and the cheese efect. Neurochem Res, 18: 1145-1149. (Pubitemid 23306348)
3. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C. (2007). Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol, 47: 1256-1267.
4. Barrett JS, DiSanto AR, Tomford PJ, Larsen EM, Palazzolo MJ, Morales RJ. (1997). Toxicokinetic evaluation of a selegiline transdermal system in the dog. Biopharm Drug Dispos, 18: 165-184.
5. Blackwell B, Marley E, Price J, Taylor D. (1967). Hypertensive interactions between monoamine oxidase inhibitors and foodstufs. Br J Psychiatry, 113: 349-365.
6. Bounoure F, Lahiani Skiba M, Besnard M, Arnaud P, Mallet E, Skiba M. (2008). Efect of iontophoresis and penetration enhancers on transdermal absorption of metopimazine. J Dermatol Sci, 52: 170-177.
7. Brand RM, Guy RH. (1995a). Iontophoresis of nicotine in vitro: pulsatile drug delivery across the skin?. J Control Release, 33: 285-292.
8. Brand RM, Guy RH. (1995b). Rapid transdermal delivery of nicotine by iontophoresis. J Control Release, 33: 285-292.
9. Burnette RR, Ongpipattanakul B. (1987). Characterization of the permselective properties of excised human skin during iontophoresis. J Pharm Sci, 76: 765-773.
10. Chrisp P, Mammen GJ, Sorkin EM. (1991). Selegiline. A review of its pharmacology, symptomatic benefts and protective potential in Parkinson's disease. Drugs Aging, 1: 228-248.
11. Delgado-Charro MB, Rodriguez-bayon AM, Guy RH. (1995). Iontophoresis of nafarelin: efects of current density and concentration on electrotransport in vitro. J Control Release, 35: 35-40.
12. Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P. (1978). Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese efect'. Psychopharmacology (Berl), 57: 33-38.
13. Fang JY, Hung CF, Chi CH, Chen CC. (2009). Transdermal permeation of selegiline from hydrogel-membrane drug delivery systems. Int J Pharm, 380: 33-39.
14. Feiger AD, Rickels K, Rynn MA, Zimbrof DL, Robinson DS. (2006). Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, doble-blind, placebo-controlled, fexible-dose titration trial. J Clin Psychiatry, 67: 1354-1361.
15. Green PG, Hinz RS, Cullander C, Yamane G, Guy RH. (1991). Iontophoretic delivery of amino acids and amino acid derivatives across the skin in vitro. Pharm Res, 8: 1113-1120.
16. Hirvonen J, Guy RH. (1997). Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. Pharm Res, 14: 1258-1263.
17. Howland RH. (2006). Transdermal selegiline: a novel MAOI formulation for depression. J Psychosoc Nurs Ment Health Serv, 44: 9-12.
18. Kasha PC, Banga AK. (2008). A review of patent literature for iontophoretic delivery and devices. Recent Pat Drug Deliv Formul, 2: 41-50.
19. Kasting GB, Keister JC. (1989). Application of electrodifusion theory for a homogeneous membrane to iontophoretic transport through skin. J Control Release, 8: 195-210.
20. Knoll J. (1986). Te pharmacology of (-)deprenyl. J Neural Transm Suppl, 22: 75-89.
21. Kolli CS, Banga AK. (2008). Characterization of solid maltose microneedles and their use for transdermal delivery. Pharm Res, 25: 104-113.
22. Pae CU, Lim HK, Han C, Neena A, Lee C, Patkar AA. (2007). Selegiline transdermal system: current awareness and promise. Prog Neuropsychopharmacol Biol Psychiatry, 31: 1153-1163.
23. Patkar AA, Pae CU, Masand PS. (2006). Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr, 11: 363-375.
24. Phipps JB, Gyory JR. 1992. Transdermal ion migration. Adv Drug Deliv Rev, 9: 137-176.
25. Phipps JB, Scott ER, Gyory JR, Padmanabhan RV. (2002). Iontophoresis. In Swarbrick J, Boylan JC, eds. Enyclopedia of Pharmaceutical Technology (pp. 1573-1587). 2 ed. New York: Marcel Dekker.
26. Pickar D, Cohen RM, Jimerson DC, Murphy DL. (1981). Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity. Psychopharmacology (Berl), 74: 4-7.
27. Riviere JE, Heit MC. (1997). Electrically-assisted transdermal drug delivery. Pharm Res, 14: 687-697.
28. Tetrud JW, Koller WC. (2004). A novel formulation of selegiline for the treatment of Parkinson's disease. Neurology, 63: S2-S6.
29. Wong KS, Lu CS, Shan DE, Yang CC, Tsoi TH, Mok V. (2003). Efcacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. J Neurol Sci, 216: 81-87.